Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). $140.5M estimated net proceeds from equity offering, strengthening Replimune’s cash resources.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $140.5M estimated net proceeds from equity offering, strengthening Replimune’s cash resources
- 9.70M common shares priced at $12.06 plus pre-funded warrants for 2.74M shares at $12.0599
- Potential dilution of up to 12.44M shares, including warrant shares
- Pre-funded warrants exercisable immediately with a 9.99% beneficial-ownership blocker
- Expected closing August 11, 2026, subject to customary conditions
Item EX-99.1 · Exhibit EX-99.1
- $150.0M gross proceeds from underwritten offering, strengthening funding for commercialization and clinical programs
- 9,701,490 shares priced at $12.06, creating immediate equity dilution for existing shareholders
- Pre-funded warrants for 2,736,340 shares add potential dilution at a $0.0001 exercise price
- Expected closing August 11, 2026, subject to customary conditions
- Capital raise supports a company facing confirmatory Phase 3 and manufacturing execution risks for TUDRIQEV
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.